Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters
 

Breast Cancer Clinical Trials

A listing of Breast Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (119) clinical trials

The relatively restricted C4.4a expression pattern provides a target for the selective delivery of a cytotoxic drug to C4.4.a-expressing tumor cells by means of a suitable antibody-drug conjugate. The subject population eligible for the current study will be those subjects with advanced malignancies known to express C4.4a, which are refractory ...

Phase

BAY 1217389 is a potent and highly selective inhibitor of monopolar spindle 1 (MPS1) kinase activity. Human MPS1 is a serine threonine kinase, which functions as a core component of the spindle-assembly checkpoint (SAC), a key surveillance mechanism that monitors the attachment of spindle microtubules to the kinetochores of the ...

Phase

To characterize the safety, tolerability, pharmacokinetics and immunogenicity of anetumab ravtansine in subjects with advanced solid cancers and with different degrees of hepatic or renal impairment

Phase

Safety Study of Combined Immunotherapy With Trastuzumab and Cetuximab in Patients With Metastatic Breast Cancer

One important approach to change the natural history of advanced breast cancer is that of designing new combination chemotherapies in which the best drugs already available are used together with new anticancer agents devoid of clinical cross-resistance. The possibility of exploiting the combined use of cetuximab and trastuzumab represents an ...

Phase

Breast Imaging Using Indium In 111 CHX-A DTPA Trastuzumab in Patients With Primary Cancer or Metastatic Cancer

OBJECTIVES: Primary - Correlate the uptake of indium In 111 CHX-A DTPA trastuzumab (indium In 111 Herceptin^®) with HER2 status as determined by fluorescent in situ hybridization (FISH) in patients with primary or metastatic cancer. Secondary - Determine the safety of this drug in these patients. - Determine the optimal ...

Phase

Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery

PRIMARY OBJECTIVES: I. To determine the optimal biologic dose (OBD) for poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibition using irinotecan (irinotecan hydrochloride) (once weekly intravenously in 2 of 3 weeks), in combination with ABT-888 (veliparib) (twice daily orally for 2 of 3 weeks). (ORIGINAL DOSE ESCALATION PORTION) II. To determine ...

Phase

Optical Spectroscopy in Evaluating Tumor Margins in Patients Who Have Undergone Surgery for Breast Tumors

OBJECTIVES: - To develop a non-invasive detection tool that evaluates breast tumor margins in real-time to guide tumor resection during partial mastectomy procedures. - To conduct an ex vivo optical spectroscopic study in operating rooms on breast tissue samples obtained immediately following resection to assess the efficacy of using this ...

Phase

AZD2281 and Carboplatin in Treating Patients With BRCA1/BRCA2-Associated Hereditary or Triple Negative Metastatic or Unresectable Breast Cancer or Ovarian Epithelial Cancer

OBJECTIVES: Primary - Determine the safety and toxicity of AZD2281 and carboplatin in patients with BRCA1/BRCA2-associated or familial breast or ovarian epithelial cancer, low genetic risk sporadic ovarian serous epithelial cancer, or low genetic risk triple negative breast cancer. - Determine the biochemical changes in poly (ADP-ribose) polymerase (PARP) activity ...

Phase

A Phase I Cancer Vaccine Study for Patients With Metastatic Breast Cancer

The study is an open-label study to assess safety and immune responses to the universal tumor antigen OFA/iLRP. All patients will be immunized with 1 x 107 viable OFA/iLRP-loaded mature, autologous monocyte-derived dendritic cells (DCs). The DC vaccine will be administered intradermally into the proximal medial upper extremity, contralateral to ...

Phase

Dasatinib and Bevacizumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot be Removed by Surgery

OBJECTIVES: Primary - To describe the safety and toxicity of the combination of dasatinib and bevacizumab in patients with advanced solid tumors that have progressed on standard therapy. - To find the maximum tolerated dose or recommended phase II dose of this combination. - To describe the biochemical changes in ...

Phase